Our lead DNase program, XBIO-015, is initially being developed for pancreatic carcinoma and other solid tumors.

XBIO-015 Has the Potential to Improve Current Cancer Therapies

Overcome T cell exclusion and immunosuppressive
 signals by the tumor microenvironment (TME)

Improve side effect profiles of current ChemoRx

XBIO-015 is Enzyme Designed to Destroy NETs

Learn More About NETs and Their Roll as a Driver of Cancer Progression and Metastasis and How They Can Contribute to Cancer Therapies Resistance

XBIO-015 is Initially Targeting Pancreatic Carcinoma